GSK Plc (GSK)
48.13
+0.01
(+0.02%)
USD |
NYSE |
Sep 11, 16:00
48.12
-0.01
(-0.02%)
After-Hours: 20:00
GSK Enterprise Value : 116.82B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 116.82B |
| September 10, 2026 | 116.79B |
| September 09, 2026 | 117.83B |
| September 08, 2026 | 117.64B |
| September 04, 2026 | 120.38B |
| September 03, 2026 | 122.36B |
| September 02, 2026 | 121.49B |
| September 01, 2026 | 121.93B |
| August 31, 2026 | 121.10B |
| August 28, 2026 | 122.26B |
| August 27, 2026 | 121.14B |
| August 26, 2026 | 123.49B |
| August 25, 2026 | 124.78B |
| August 24, 2026 | 124.20B |
| August 21, 2026 | 125.47B |
| August 20, 2026 | 124.56B |
| August 19, 2026 | 126.42B |
| August 18, 2026 | 122.92B |
| August 17, 2026 | 121.16B |
| August 14, 2026 | 119.63B |
| August 13, 2026 | 121.51B |
| August 12, 2026 | 121.20B |
| August 11, 2026 | 122.42B |
| August 10, 2026 | 124.97B |
| August 07, 2026 | 126.58B |
| Date | Value |
|---|---|
| August 06, 2026 | 124.99B |
| August 05, 2026 | 123.55B |
| August 04, 2026 | 123.69B |
| August 03, 2026 | 123.65B |
| July 31, 2026 | 124.02B |
| July 30, 2026 | 124.78B |
| July 29, 2026 | 127.11B |
| July 28, 2026 | 128.10B |
| July 27, 2026 | 124.60B |
| July 24, 2026 | 123.33B |
| July 23, 2026 | 122.09B |
| July 22, 2026 | 122.13B |
| July 21, 2026 | 122.18B |
| July 20, 2026 | 120.68B |
| July 17, 2026 | 124.16B |
| July 16, 2026 | 126.20B |
| July 15, 2026 | 123.53B |
| July 14, 2026 | 123.13B |
| July 13, 2026 | 125.23B |
| July 10, 2026 | 126.22B |
| July 09, 2026 | 125.59B |
| July 08, 2026 | 125.69B |
| July 07, 2026 | 127.31B |
| July 06, 2026 | 126.85B |
| July 02, 2026 | 128.00B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 523.09B |
| Eli Lilly & Co. | 1.096T |
| Merck & Co., Inc. | 402.09B |
| Novo Nordisk A/S | 158.66B |
| Novartis AG | 292.81B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 742.26M |
| Revenue (Quarterly) | 11.29B |
| Total Expenses (Quarterly) | 10.70B |
| EPS Diluted (Quarterly) | 0.2875 |
| Gross Profit Margin (Quarterly) | 75.05% |
| Profit Margin (Quarterly) | 6.58% |
| Earnings Yield | 6.59% |
| Operating Earnings Yield | 11.34% |
| Normalized Earnings Yield | 9.582 |